Pediatric Priority Review Voucher Program. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Global supply chain and investment issues. Prescription drug pricing policy.
2026 · 2nd Quarter (Apr 1 - June 30)
ASTRAZENECA PHARMACEUTICALS LP
Filed by TODD STRATEGY GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- TODD STRATEGY GROUP
- Filing UUID
- 2d54b2b8-3407-49af-9a40-e0fedd53984b
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
340B Program. Home Infusion for Part B Products. S.864: HELP Copays Act. Medicare Reimbursement for New Technologies.
Literal federal measure citations: S.864
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.